Ezio Bonvini

Best Publications

• CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

  Robbie G. Majzner;Johanna L. Theruvath;Anandani Nellan;Sabine Heitzeneder

  639
  Citations

• Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.

  Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain

  560
  Citations

• Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors

  Jeffrey B. Stavenhagen;Sergey Gorlatov;Nadine Tuaillon;Christopher T. Rankin

  521
  Citations

• Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

  Paul A. Moore;Wenjun Zhang;G. Jonah Rainey;Steve Burke

  473
  Citations

• Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

  Deryk Loo;Ralph F. Alderson;Francine Z. Chen;Ling Huang

  378
  Citations

• Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells

  Kavita M. Dhodapkar;Jacob L. Kaufman;Marc Ehlers;Devi K. Banerjee

  356
  Citations

• Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

  Syd Johnson;Stephen Burke;Ling Huang;Sergey Gorlatov

  332
  Citations

• Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.

  Hope S. Rugo;Seock Ah Im;Fatima Cardoso;Javier Cortés

  318
  Citations

• Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

  Geoffrey L. Uy;Ibrahim Aldoss;Matthew C. Foster;Peter H. Sayre

  307
  Citations

• Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

  Jeffrey L Nordstrom;Sergey Gorlatov;Wenjun Zhang;Yinhua Yang

  299
  Citations

• Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization

  Maria-Concetta Veri;Sergey Gorlatov;Hua Li;Steve Burke

  275
  Citations

• Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

  William Hagopian;Robert J. Ferry;Nicole Sherry;David Carlin

  260
  Citations

• Therapeutic Control of B Cell Activation via Recruitment of Fcγ Receptor IIb (CD32B) Inhibitory Function With a Novel Bispecific Antibody Scaffold

  Maria-Concetta Veri;Stephen Burke;Ling Huang;Hua Li

  207
  Citations

• A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.

  Gurunadh R. Chichili;Ling Huang;Hua Li;Steve Burke

  189
  Citations

• Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

  Muneera Al-Hussaini;Michael P. Rettig;Julie K. Ritchey;Darja Karpova

  189
  Citations

• Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

  Unknown

  188
  Citations

• CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma

  Christopher T. Rankin;Maria-Concetta Veri;Sergey Gorlatov;Nadine Tuaillon

  171
  Citations

• Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.

  Juniper A Scribner;Jennifer G Brown;Thomas Son;Michael Chiechi

  149
  Citations

• Costimulation of T cell receptor/CD3-mediated activation of resting human CD4+ T cells by leukocyte function-associated antigen-1 ligand intercellular cell adhesion molecule-1 involves prolonged inositol phospholipid hydrolysis and sustained increase of intracellular Ca2+ levels.

  G A Van Seventer;E Bonvini;H Yamada;A Conti

  146
  Citations

• Tumor Necrosis Factor {alpha} (TNF-{alpha}) Activates Jak1/Stat3-Stat5B Signaling through TNFR-1 in Human B Cells

  Sebastiano Miscia;Marco Marchisio;Alfredo Grilli;Valentina Di Valerio

  136
  Citations